Tango Combo Posts 82% Response in Pancreatic Cancer — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Rasonque was paired with an experimental Tango Therapeutics drug; the combination produced tumor responses in 82% of patients with a certain type of advanced pancreatic cancer.
- The trial’s nine-month assessment found that 88% of patients were still alive without tumor progression, supporting the durability of the responses.
- The Tango regimen omitted chemotherapy, long considered the standard treatment for aggressive pancreatic cancer.
- The new data bolster the theory that pancreatic cancer patients can derive more benefit from combinations of targeted drugs than from single drugs.
Why it matters: For Tango Therapeutics and Revolution Medicines, the 82% response rate and the fact that 88% of patients remained alive without progression at nine months provide direct clinical support for combining their drugs. For patients in the trial’s particular advanced pancreatic cancer type, the regimen also supplies evidence of response without chemotherapy, long considered standard.
Ask SkimNews
